Factors such as the increasing burden of chronic diseases and rising technological advancements for cost-effective production of catalog peptides, and soaring number of research activities to address the unmet medical needs in several therapeutic areas will aid the catalog peptides market to progress at 5.8% CAGR during the forecast period (2019–2024).
The rapid evolution in peptide and drug production technologies is one of the key contributors to the market growth, globally. The advent of new manufacturing technologies can be attributed to the increasing number of research activities being carried out for meeting the unmet therapeutic needs for numerous chronic ailments, such as respiratory disorders, diabetes, cancer, and ischemic heart diseases. These researches are aimed at developing new cost-effective drugs and are funded by government organizations and national academic institutes peptide calculator.
At present, the rising number of research activities aimed at protein and product launches is becoming a prominent trend in the catalog peptides market. Recombinant deoxyribonucleic acid (DNA) technology is viewed as one of the most effective molecular biology techniques in the domain of life sciences for the production of biopharmaceuticals. This technology can produce an abundant volume of desired and purified recombinant proteins, which can be used in the diagnosis and treatment of diseases.
The type segment of the catalog peptides market is categorized into G-protein-coupled receptors (GPCR), calcitonin gene-related, caspase related, anti-microbial, cyclic, amyloid, amylin, tau, adrenomedullin, cosmetic, and others. Under this segment, the cyclic category accounted for the largest share during the historical period (2014–2018), and it is expected to retain its dominance throughout the forecast period as well. This can be credited to the exceptional stability and excellent binding affinity offered by cyclic peptides. This type of catalog peptide can be used in anti-tumor, anti-bacterial, and immunosuppressive activities.
According to P&S Intelligence, North America held the largest share in the catalog peptides market in 2018, and it will continue this trend during the forecast period as well. This can be owed to the strong presence of established players and hefty investments and funds being allocated to research and development (R&D) in protein synthesis in the region. Moreover, the increasing adoption of advanced peptide production technologies will also facilitate the market growth in the region in the forthcoming years.